Zynerba Pharmaceuticals
Dedicated to the development of innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders
Our mission is to improve the lives of patients battling severe rare and near-rare neuropsychiatric disorders including Fragile X syndrome and certain refractory epilepsies including developmental and epileptic encephalopathies (DEE).
Our Team
Our team has a proven track record of success in developing novel transdermal products for patients in need.
Our Development Pipeline
We are developing a proprietary pharmaceutically-produced transdermally-delivered CBD gel in multiple neuropsychiatric indications, including Fragile X syndrome and certain refractory epilepsies.
Latest News
1212
Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
1120